Pipeline Speed Bump Doesn't Shake AstraZeneca's $80 Billion Revenue Ambition
AstraZeneca Plc (NASDAQ: AZN ) on Monday posted mixed second-quarter 2026 results, beating Wall Street’s earnings estimates while falling short on revenue. The drugmaker also reported disappointing late-stage trial results for two experimental therapies, including a Phase 3 study of Ultomiris. AstraZeneca Beats Earning